Return to homepagePandemic Pact

Hilleman Business Plan FY2025-FY2030

Grant number: 310051/Z/24/Z

Grant search

Key facts

  • Disease

    Lassa Haemorrhagic Fever, Infection caused by Nipah virus…

  • Start & end year

    2025
    2029

  • Known Financial Commitments (USD)

    $35,366,621.7

  • Funder

    Wellcome Trust

  • Principal Investigator

    Dr. Raman Rao

  • Research Location

    Singapore

  • Lead Research Institution

    Hilleman Laboratories Singapore Pte Ltd

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Not applicable

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Since April 2021, Hilleman expanded its vaccine portfolio from cholera and meningitis to viral, recombinant and mRNA vaccines. We invested in four vaccine platforms and raised $39.1M in external funding to support our infrastructure and operations. From 2025-2027, we will oversee the implementation of Hillchol™in India and GAVI countries, complete the development and licensure of Ervebo® second generation with our collaborators, advance MenACWYX, CircRNA-Nipah, Lassa and Q-Fever vaccines to Phase I through external funding and partnerships, and manufacture 5 GMP batches at ACES. The implementation of Hillchol™, Ervebo®, Lassa, Nipah and MenACWYX vaccines could impact disease burden for 150M people in LMICs with a potential for 500M more with vaccines against other endemic diseases.